Shenyang Xingqi PharmaceuticalLtd Future Growth
Future criteria checks 6/6
Shenyang Xingqi PharmaceuticalLtd is forecast to grow earnings and revenue by 32.8% and 22.6% per annum respectively. EPS is expected to grow by 32.9% per annum. Return on equity is forecast to be 22.1% in 3 years.
Key information
32.8%
Earnings growth rate
32.9%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 22.6% |
| Future return on equity | 22.1% |
| Analyst coverage | Low |
| Last updated | 23 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/E Is Still On The Mark Following 49% Share Price Bounce
Oct 23
Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stocks Pounded By 30% But Not Lagging Market On Growth Or Pricing
Sep 08With EPS Growth And More, Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Makes An Interesting Case
Aug 19What You Can Learn From Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/S After Its 27% Share Price Crash
Jul 24Does Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Have A Healthy Balance Sheet?
Jun 28Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Increasing Its Dividend To CN¥3.00
May 21After Leaping 31% Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares Are Not Flying Under The Radar
May 10We Ran A Stock Scan For Earnings Growth And Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Passed With Ease
May 07Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Looks Just Right With A 26% Price Jump
Mar 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,082 | 768 | N/A | 1,474 | 1 |
| 12/31/2025 | 2,680 | 669 | N/A | 1,171 | 1 |
| 12/31/2024 | 2,117 | 449 | N/A | 867 | 1 |
| 9/30/2024 | 1,802 | 348 | 270 | 447 | N/A |
| 6/30/2024 | 1,674 | 322 | 211 | 400 | N/A |
| 3/31/2024 | 1,531 | 255 | 153 | 343 | N/A |
| 12/31/2023 | 1,468 | 240 | 56 | 318 | N/A |
| 9/30/2023 | 1,350 | 191 | 8 | 254 | N/A |
| 6/30/2023 | 1,335 | 179 | 27 | 256 | N/A |
| 3/31/2023 | 1,234 | 157 | -103 | 241 | N/A |
| 1/1/2023 | 1,250 | 212 | -13 | 286 | N/A |
| 9/30/2022 | 1,262 | 241 | 90 | 378 | N/A |
| 6/30/2022 | 1,166 | 235 | 80 | 362 | N/A |
| 3/31/2022 | 1,123 | 236 | 234 | 363 | N/A |
| 1/1/2022 | 1,028 | 195 | 212 | 307 | N/A |
| 9/30/2021 | 990 | 190 | 156 | 243 | N/A |
| 6/30/2021 | 914 | 153 | 92 | 186 | N/A |
| 3/31/2021 | 813 | 132 | 68 | 167 | N/A |
| 12/31/2020 | 689 | 88 | 14 | 122 | N/A |
| 9/30/2020 | 602 | 61 | 0 | 81 | N/A |
| 6/30/2020 | 528 | 45 | -28 | 51 | N/A |
| 3/31/2020 | 514 | 24 | -21 | 64 | N/A |
| 12/31/2019 | 542 | 36 | 4 | 74 | N/A |
| 9/30/2019 | 504 | 29 | -9 | 62 | N/A |
| 6/30/2019 | 480 | 21 | -13 | 45 | N/A |
| 3/31/2019 | 453 | 17 | 4 | 48 | N/A |
| 12/31/2018 | 431 | 14 | -1 | 44 | N/A |
| 9/30/2018 | 416 | 11 | 8 | 58 | N/A |
| 6/30/2018 | 379 | 9 | N/A | 63 | N/A |
| 3/31/2018 | 362 | 28 | N/A | 28 | N/A |
| 12/31/2017 | 360 | 39 | N/A | 33 | N/A |
| 9/30/2017 | 361 | 51 | N/A | 11 | N/A |
| 6/30/2017 | 356 | 51 | N/A | 10 | N/A |
| 3/31/2017 | 347 | 55 | N/A | 32 | N/A |
| 12/31/2016 | 339 | 54 | N/A | 28 | N/A |
| 12/31/2015 | 287 | 22 | N/A | 21 | N/A |
| 12/31/2014 | 255 | 31 | N/A | 13 | N/A |
| 12/31/2013 | 219 | 46 | N/A | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300573's forecast earnings growth (32.8% per year) is above the savings rate (2.8%).
Earnings vs Market: 300573's earnings (32.8% per year) are forecast to grow faster than the CN market (26.2% per year).
High Growth Earnings: 300573's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300573's revenue (22.6% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 300573's revenue (22.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300573's Return on Equity is forecast to be high in 3 years time (22.1%)